Physical Activity and Fatigue in Early Multiple Sclerosis (MS)

NCT ID: NCT00882453

Last Updated: 2012-05-30

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Total Enrollment

1739 participants

Study Classification

OBSERVATIONAL

Study Start Date

2006-08-31

Study Completion Date

2011-03-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The purpose of this observational study is to obtain a survey on physical activity in patients who for the first time have experienced symptoms which indicate a high risk for developing multiple sclerosis (MS) and in patients with recently diagnosed MS, and to obtain information on factors potentially influencing the patients' level of activity.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Multiple Sclerosis

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

PROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Group 1

Interferon beta-1b (Betaseron, BAY86-5046)

Intervention Type DRUG

Intravenous therapy according to product information

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Interferon beta-1b (Betaseron, BAY86-5046)

Intravenous therapy according to product information

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Multiple sclerosis diagnosed within the last 12 months
* Clinically isolated Syndrome (CIS), under Interferon-beta-1b treatment
Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Bayer

INDUSTRY

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Bayer Healthcare AG

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Bayer Study Director

Role: STUDY_DIRECTOR

Bayer

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Many Locations, , Australia

Site Status

Many Locations, , Austria

Site Status

Many Locations, , Bahrain

Site Status

Many Locations, , Belgium

Site Status

Many Locations, , Canada

Site Status

Many Locations, , Colombia

Site Status

Many Locations, , Czechia

Site Status

Many Locations, , Denmark

Site Status

Many Locations, , Egypt

Site Status

Many Locations, , France

Site Status

Many Locations, , Germany

Site Status

Many Locations, , Greece

Site Status

Many Locations, , Indonesia

Site Status

Many Locations, , Israel

Site Status

Many Locations, , Italy

Site Status

Many Locations, , Jordan

Site Status

Many Locations, , Kazakhstan

Site Status

Many Locations, , Kuwait

Site Status

Many Locations, , Lebanon

Site Status

Many Locations, , Mexico

Site Status

Many Locations, , Netherlands

Site Status

Many Locations, , Norway

Site Status

Many Locations, , Oman

Site Status

Many Locations, , Portugal

Site Status

Many Locations, , Slovenia

Site Status

Many Locations, , South Korea

Site Status

Many Locations, , Spain

Site Status

Many Locations, , Sweden

Site Status

Many Locations, , Switzerland

Site Status

Many Locations, , Taiwan

Site Status

Many Locations, , Thailand

Site Status

Many Locations, , United Arab Emirates

Site Status

Many Locations, , United Kingdom

Site Status

Countries

Review the countries where the study has at least one active or historical site.

Australia Austria Bahrain Belgium Canada Colombia Czechia Denmark Egypt France Germany Greece Indonesia Israel Italy Jordan Kazakhstan Kuwait Lebanon Mexico Netherlands Norway Oman Portugal Slovenia South Korea Spain Sweden Switzerland Taiwan Thailand United Arab Emirates United Kingdom

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

BF0601

Identifier Type: OTHER

Identifier Source: secondary_id

310721

Identifier Type: OTHER

Identifier Source: secondary_id

13853

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

BENEFIT Extension Study
NCT00544037 COMPLETED